Internationally Accredited! Qirui Technology Earns ACCA Recognized Employer Status
Category: News and Information
Release Date: 2025-07-08
Summary: On July 8, 2024, Wuhan Qirui Technology Development Co., Ltd. officially passed the rigorous assessment conducted by ACCA (the Association of Chartered Certified Accountants) and was awarded the prestigious global accounting and finance qualification of ACCA Approved Employer.
On July 8, 2024, Wuhan Qirui Technology Development Co., Ltd. officially passed the rigorous ACCA (Association of Chartered Certified Accountants) examination. grid Review, Awarded Global authoritative qualification in the finance and accounting field —— ACCA-Accredited Employer 。 June 20, 2025, at ACCA Co-organized with the Hubei Provincial Association of Chief Accountants “2025 ACCA Chief Financial Officer Summit – Wuhan Station & ACCA Wuhan 10th Anniversary Celebration” Above, Qirui Group Wan Jincheng, CFO and ACCA Senior Member Total From Solemnly received from Mr. Yu Xiangtian, Director of ACCA China Mainland Affairs “ACCA-Accredited Employer” certificate. This marks Qirui Technology’s financial and accounting talent development system. Success Obtain authoritative certification from the world’s most influential accounting organization. 。

Yu Xiangtian, Director of ACCA China Mainland Affairs, presented the “ACCA Recognized Employer” certificate to Wuhan Qirui Technology Development Co., Ltd.
The ACCA Approved Employer Scheme is a key benchmark for assessing an organization’s level of international financial management and its capability in talent development. To date, Only worldwide 7,959 enterprises Obtain this qualification 。 This Certifies corporate financial management capabilities Compliant with Triple International Accreditation Standard : Gold Standard for Talent Development 、 Apply high standards in practice 、 Hard Power for Cross-Border Passage 。

ACCA Recognised Employer Certificate
In the pharmaceutical and healthcare sector, ACCA professionals, with their expertise in international tax planning and cross-border compliance and risk management, are pivotal to pharmaceutical companies’ global expansion. Support As a technology enterprise rooted in Wuhan, Qirui Group Having two ACCA Senior Member – Group CFO Wan Jincheng Total With Finance COE Manager Zhu Heng, They adopt an international accounting and finance perspective to Company Professional and specialized management injects a dual-engine drive.

Mr. Wan Jincheng, Group CFO
In “The Breakthrough | Functional Leap: Panel Discussion—Financial Transformation as a Catalyst for Value Creation” session, Wan Jincheng Total Shared Qirui Group The transformation of the finance function from traditional accounting to business-driven, value-creating roles, from Comprehensive value empowerment, shifting from “post-event accounting” to “pre-event forecasting, in-process control, and post-event feedback.” and and Conversation Guest In-depth exploration of the value transformation pathway for financial functions in the digital intelligence era. 。

“Breaking the Impasse | Functional Leapfrogging: Panel Discussion – Financial Transformation as a Catalyst for Value Creation”

to do for National High-tech Enterprise , Qirui Group Deep cultivation Areas of disease including liver disorders, cardiovascular and cerebrovascular diseases, digestive disorders, fungal infections, and respiratory diseases More than two decades of drug discovery and development. The company has consistently upheld “ Quality and Responsibility ” of Values , regard talent as the most valuable asset.
This time Obtain ACCA Recognizing employer qualifications is not only Marks Qirui Group Financial Management System Obtain International Authority Certification, more Become Talent Strategy in the Process of Corporate Globalization of Important Milestone. In the future, Qirui Group Will rely on ACCA With a global network, we continuously recruit versatile finance professionals with an international perspective to tackle major diseases and improve human health. Contribute solid financial strength!
Let professionalism and a spirit of innovation take root and flourish in Qirui’s environment, ensuring that every financial statement conveys the value of life.
Correspondent: Zhu Heng
Keywords: Internationally Accredited! Qirui Technology Earns ACCA Recognized Employer Status
Related News Centers
Academic Column
Development History
-
2019
Release time:2023-01-05
-
2018
Release time:2023-01-05
-
2017
Release time:2023-01-05
-
2014
Release time:2023-01-05
-
2013
Release time:2023-01-05
-
2012
Release time:2023-01-05
-
2011
Release time:2023-01-05
-
2010
Release time:2023-01-05
-
2009
Release time:2023-01-05
-
2008
Release time:2023-01-05
-
2007
Release time:2023-01-05
-
2006
Release time:2023-01-05
-
2005
Release time:2023-01-05
-
2004
Release time:2022-12-30
-
2003
Release time:2022-12-30
Branch office
News and Information
-
Qirui Group’s First Innovative Drug, MY008211A Tablets (Lanocapam Hydrochloride Tablets), Successfully Achieves the Primary Efficacy Endpoint in Phase III Clinical Trials
Release time:2026-02-25
-
Qirui Group’s First Innovative Drug Passes Both National Key Inspections on the First Attempt
Release time:2026-01-27
-
Three Employees of Qirui Pharmaceutical Awarded Jiangxia District’s Tangxun Lake Talent Recognition!
Release time:2026-01-15
-
“A ‘Start’ That Stands Out, Bringing in Talented Young Professionals — Qirui Group’s 2026 Campus Recruitment Concludes Successfully”
Release time:2025-12-31
-
Qirui Pharmaceutical’s Ganyining® Ademetionine Disulfonate for Injection Wins Bid in the 11th National Centralized Procurement Round
Release time:2025-11-11
-
Qirui Group Makes Its Debut at the 17th Bio-Industry Conference
Release time:2025-09-08
-
Empowering Your Journey, Illuminating the Path Ahead—Qirui Group’s 2025 New Graduate Onboarding Program Concludes Successfully
Release time:2025-07-23
-
Internationally Accredited! Qirui Technology Earns ACCA Recognized Employer Status
Release time:2025-07-08
-
Safeguarding the Source of Life and Fortifying the Quality Defense Line for Pharmaceutical Water — Professional Training on Purified Water Systems at Qirui Pharmaceutical
Release time:2025-06-05
-
Wuhan Qirui Technology Development Co., Ltd. Donates RMB 100 Million to Huazhong University of Science and Technology
Release time:2025-03-17
-
People-Oriented, Win-Win Future | Qirui Pharmaceutical Honored as “2024 China’s Top Employer”
Release time:2025-02-18
-
Empowering Party Building to Unite New Forces, Achieve Synergy, and Expand “Health”
Release time:2024-07-10
-
Qirui Group Makes Its Debut at CPHI China 2024
Release time:2024-06-28
-
Enhancing Competence Through Competition and Pursuing Development Through Quality: Qirui Pharmaceutical Successfully Holds Its 2024 Annual Quality Knowledge Competition
Release time:2024-06-28
-
Shining with the Light of Wisdom, Passing on the Torch of Scholarship — The Joint Master’s Thesis Defense Ceremony between Qirui Pharmaceutical and China Pharmaceutical University Concludes Successfully
Release time:2024-06-07
-
Academic Gala | The 8th International Forum on Drug-Induced Liver Injury Concludes Successfully; Ornithine Aspartate Recommended in the “Chinese Guidelines for Primary Care Diagnosis and Management of Drug-Induced Liver Injury (2024)”
Release time:2024-05-31
-
Qirui Pharmaceutical Awarded the “Wuhan May Day Labor Medal”
Release time:2024-05-13
-
Qirui Pharmaceutical Selected for Inclusion in the 2023 Jiangxia District List of Proposed Projects for District-Level Technology Transfer and Key R&D Initiatives
Release time:2024-04-12
-
“Made in Wuhan” Generic Drugs Added to the 2020 National Reimbursement Drug List
Release time:2021-03-05
-
Congratulatory Letter to Shandong Ruiyin Bioengineering Co., Ltd.
Release time:2021-02-01
-
Douyin Live Stream Coverage | Qirui’s 2020 Annual Work Summary and Awards Ceremony Held Successfully!
Release time:2021-01-28
-
First Public Notice of the Environmental Impact Assessment for the Demonstration Project on the Transformation and Construction of a Multi-Functional, Intelligent, Safe, Green, and High-End Active Pharmaceutical Ingredient Production Platform and Pilot-Scale Service Platform at Wuhan Zhongyou Pharmaceutical Co., Ltd.
Release time:2020-06-28
-
Decision on Commending the 2020 Pioneers in Epidemic Prevention Responsibility and Model Workers in Resuming Work and Production
Release time:2020-05-11
-
Notice of the Renewal of the Employee Care and Corporate Culture Development Committee
Release time:2020-04-27
Sunshine Avenue, Sunshine Third Road, Miaoshan Subdistrict, Economic Development Zone, Jiangxia District, Wuhan, Hubei Province
QR code
Copyright © Wuhan Qirui Pharmaceutical Co., Ltd. |Privacy Policy
Powered by www.300.cn
This website supports IPv6.